Name | 4-amino-N-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide,(2R,3R)-2,3-dihydroxybutanedioic acid |
---|---|
Synonyms |
UNII-2Z90GEN540
cinitapride tartrate Cinitapride hygrogen tartrate |
Description | Cinitapride monotartrate is a 5-HT1A and 5-HT4 agonist. Cinitapride monotartrate is also a 5-HT2A and D2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia[1][2]. |
---|---|
Related Catalog | |
Target |
5-HT2 Receptor 5-HT1 Receptor 5-HT4 Receptor D2 Receptor |
In Vivo | Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model[2]. Animal Model: Male Wistar rats with gastric ulceration[2] Dosage: 0.25-1 mg/kg Administration: Intraperitoneal injection; 0.25-1 mg/kg; once Result: Reduced haemorrhagic lesions compared with the ulcerated control group. Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg). Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01). Increased GSH-px activity in the gastric mucosa. |
References |
Molecular Formula | C25H36N4O10 |
---|---|
Molecular Weight | 552.57 |
Exact Mass | 552.24300 |
PSA | 231.96000 |
LogP | 2.62070 |